Oncology Corporate Profile
This company does not have any pipeline products
8/16/2016 10:02 am
8/16/2016 10:02 am
8/2/2016 08:00 pm
8/1/2016 09:01 pm
7/28/2016 08:00 pm
7/27/2016 04:05 pm
7/26/2016 09:04 pm
[at noodls] - July 26, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...
7/26/2016 09:02 pm
[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND’s assets.
7/26/2016 09:02 pm
7/25/2016 11:05 am
[at noodls] - July 25, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...
7/25/2016 11:00 am
[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that it has received two bids that are qualified to participate in the Court authorized auction beginning at 10 a.m.
7/6/2016 01:02 pm
7/6/2016 12:00 pm
7/1/2016 09:05 pm
[at noodls] - July 1, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS, today announced it has ...
7/1/2016 09:03 pm
[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced it has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer Inc.
6/22/2016 08:00 pm
6/17/2016 03:00 pm
6/17/2016 02:01 pm
[at noodls] - June 17, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the ...
6/17/2016 01:01 pm
6/17/2016 01:00 pm
[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the resignations of Amir Nashat, managing partner at Polaris Partners, and Amy Schulman, venture partner at Polaris Partners and chief executive officer at Arsia Therapeutics and Lyndra Therapeutics, from BIND’s Board of Directors.
5/19/2016 11:00 pm
5/19/2016 08:01 pm
5/19/2016 12:03 pm
[at noodls] - May 19, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement ...
5/19/2016 12:00 pm
[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital , for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions.
5/18/2016 05:00 pm